Autoantibodies as predictive tools in systemic sclerosis

Nature Reviews Rheumatology

Volumn 6, Issue 2, 2010, Pages 112-116

  Nihtyanova, Svetlana I ^a   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KU ANTIBODY; PHOSPHOLIPID ANTIBODY; PM SCL ANTIBODY; RIBONUCLEOPROTEIN U11 ANTIBODY; RIBONUCLEOPROTEIN U3 ANTIBODY; RNA POLYMERASE ANTIBODY; SCL 70 ANTIBODY; SMALL NUCLEAR RIBONUCLEOPROTEIN; TH TO RIBONUCLEOPROTEIN ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; HUMAN; IMMUNOPATHOGENESIS; LUNG FIBROSIS; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 76649085510     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.238     Document Type: Note

References (32)

1. Hénault, J., Tremblay, M., Clément, I., Raymond, Y. & Senécal, J. L. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum. 50, 3265-3274 (2004).
2. Hu, P. Q., Fertig, N., Medsger, T. A. Jr & Wright, T. M. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 48, 1363-1373 (2003).
3. Kuwana, M., Kaburaki, J., Mimori, T., Kawakami, Y. & Tojo, T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum. 43, 1074-1084 (2000).
4. Reveille, J. D. & Solomon, D. H. American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. evidencebased guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 49, 399-412 (2003).
5. Koenig, M. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58, 3902-3912 (2008).
6. Hesselstrand, R., Scheja, A., Shen, G. Q., Wiik, A. & Akesson, A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 42, 534-540 (2003).
7. Walker, U. A. et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the eULAR Scleroderma Trials and Research group database. Ann. Rheum. Dis. 66, 754-763 (2007).
8. Hachulla, e. et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR- Sclérodermie study. Rheumatology (Oxford) 48, 304-308 (2009).
9. Hamaguchi, Y. et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br. J. Dermatol. 158, 487-495 (2008).
10. Steen, v. & Medsger, T. A. Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 48, 516-522 (2003). (Pubitemid 36278021)
11. Penn, H. et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100, 485-494 (2007).
12. Rigamonti, C. et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55, 388-394 (2006).
13. Basu, D. & Reveille, J. D. Anti-scl-70. Autoimmunity 38, 65-72 (2005).
14. Gussin, H. A., Ignat, G. P., varga, J. & Teodorescu, M. Anti-topoisomerase I (anti- Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 44, 376-383 (2001).
15. Kuwana, M. et al. enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 52, 2425-2432 (2005).
16. Bunn, C. C., Denton, C. P., Shi-Wen, X., Knight, C. & Black, C. M. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br. J. Rheumatol. 37, 15-20 (1998).
17. Mitri, G. M., Lucas, M., Fertig, N., Steen, v. D. & Medsger, T. A. Jr. A comparison between anti-Th/To- and anticentromere antibodypositive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum. 48, 203-209 (2003).
18. van eenennaam, H. et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin. Exp. Immunol. 130, 532-540 (2002).
19. Tormey, v. J., Bunn, C. C., Denton, C. P. & Black, C. M. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 40, 1157-1162 (2001).
20. Aggarwal, R., Lucas, M., Fertig, N., Oddis, C. v. & Medsger, T. A. Jr. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 60, 1112-1118 (2009).
21. Fertig, N. et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis. Arthritis Rheum. 61, 958-965 (2009).
22. Raijmakers, R. et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/ scleroderma overlap syndrome. Arthritis Rheum. 50, 565-569 (2004).
23. Hanke, K. et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res. Ther. 11, R22 (2009).
24. Mahler, M. & Fritzler, M. J. The changing landscape of the clinical value of the PM/Scl autoantibody system. Arthritis Res. Ther. 11, 106 (2009).
25. Mahler, M. & Raijmakers, R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun. Rev. 6, 432-437 (2007).
26. Rozman, B. et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a european eUSTAR-initiated multi-centre case-control study. Ann. Rheum. Dis. 67, 1282-1286 (2008).
27. Ihn, H. et al. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin. Exp. Immunol. 117, 383-387 (1999). (Pubitemid 29343614)
28. Assous, N. et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin. Exp. Rheumatol. 23, 199-204 (2005).
29. Boin, F., Johnson, e., Rosen, A., Wigley, F. & Casciola-Rosen, L. Anti-beta 2 glycoprotein I antibodies are independently associated with macrovascular disease and mortality in scleroderma patients [abstract 2120]. ACR Scientific meeting (2008).
30. Steen, v. D. & Medsger, T. A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 66, 940-944 (2007).
31. Ferri, C. et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81, 139-153 (2002).
32. Silver, R. M., Bolster, M. B. & Medsger, T. A. Jr. in Arthritis and Allied Conditions: a Textbook of Rheumatology. 15th edn (eds Koopman, W. J. & Moreland, L. W.) 1633-1680 (Lippincott Williams & Wilkins, Philadelphia, 2006).